Preferred Label : Allogeneic CRISPR-edited Anti-BCMA CAR-T Cells CB-011;
NCIt synonyms : Allogeneic CRISPR-edited Anti-BCMA CAR T-cells CB-011; Allogeneic CRISPR-edited BCMA-targeted CAR T Cells CB-011;
NCIt definition : A preparation of allogeneic, off-the-shelf T-lymphocytes genetically modified and
clustered regularly interspaced short palindromic repeats (CRISPR)-edited to contain
a deletion of the TRAC gene, a site-specific insertion of a chimeric antigen receptor
(CAR) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA;
tumor necrosis factor receptor superfamily member 17; TNFRSF17) into the TRAC gene,
a deletion of the B2M gene, and a site-specific insertion of a gene encoding a B2M-HLA-E-peptide
fusion into the B2M gene, with potential immunostimulating and antineoplastic activities.
Upon administration, the allogeneic CRISPR-edited anti-BCMA CAR-T cells CB-011 recognize
and bind to BCMA-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte
(CTL)-mediated killing of BCMA-positive tumor cells. Knock out of the TRAC gene eliminates
the endogenous T-cell receptors (TCRs), thereby preventing graft-versus-host disease
(GvHD). The B2M protein is removed to eliminate endogenous HLA class I expression
on the surface of the CB-011 CAR-T cells, which protects the CAR-T cells from host
T-cell rejection. The B2M-HLA-E fusion protein is inserted to protect the CAR-T cells
from host natural killer (NK) cell rejection. BCMA, a receptor for both a proliferation-inducing
ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis
factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells,
is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation
and survival.;
Molecule name : CB-011; CB 011;
NCI Metathesaurus CUI : CL1906838;
Origin ID : C199479;
concept_is_in_subset
- has_target
